Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil

Trial Profile

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs CYD TDV (Primary)
  • Indications Dengue
  • Focus Adverse reactions
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 1 May 2019 to 18 Mar 2021.
    • 28 Jun 2017 Planned primary completion date changed from 1 May 2019 to 18 Mar 2021.
    • 28 Jun 2017 Planned initiation date changed from 1 Mar 2017 to 20 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top